logo-loader

RNC Minerals maintains 2020 production guidance amidst coronavirus outbreak

Published: 17:00 18 Mar 2020 EDT

Royal Nickel Corp -
RNC Minerals runs gold operations in Western Australia

RNC Minerals (TSE:RNX) said Wednesday that its production guidance remained unchanged in the face of the global coronavirus pandemic.

The Toronto-based company is targeting production of between 90,000-95,000 ounces at an all-in sustaining cost of between US$1,050-$1,200 per once for 2020.

The miner, which operates gold mines in Western Australia, told shareholders it had established a task force at its Australian operations led by its managing director Graham Sloan.

READ: RNC Minerals names industry veteran Barry Dahl as CFO

"RNC's number one priority is the health and safety of our employees and stakeholders,” CEO Paul Andre Huet told stakeholders in a release. “We are carefully monitoring the advice of local health authorities.”

Among the measures enacted, the company said it informed its site personnel of the precautions that need to be taken with respect to travel to and from site, along with isolation periods should anyone exhibit symptoms consistent with coronavirus.

RNC also employed a full-time nurse specifically to monitor the status of people entering and leaving our operations and sealed off ur operations from any outside visitors not critical to business operations.

In order to minimize potential disruptions to our supply chains, the company is building additional critical supplies beyond normal levels, Huet said.

“During the Australian bushfires in December and January, our ROM stockpiles proved critical in ensuring milling rates were maintained,” Huet said. “Accordingly, we are building stockpiles once again.”

Huet said its ROM stockpiles are “growing steadily” from its Baloo, Beta Hunt and the new open pit Fairplay North operations.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

8 hours, 47 minutes ago